. Two hundred iLg of membrane proteins per tube were used to assess the amount of 1251-buserelin binding.
Cancer of the prostate is the second most common cause of malignancy among males. The treatment of prostatic cancer aims to reduce serum androgen concentrations. The longacting agonist analogues of GnRH have been recently introduced as effective alternative therapies to orchiectomy and oestrogen treatment (Waxman, 1987) . Their effect on androgen dependent cell growth is thought to be mediated through down-regulation of the pituitary-gonadal axis. GnRH agonist treatment leads to an initial increase in the serum levels of LH, FSH and androgens and this may be accompanied by tumour flare (Waxman et al., 1985) . However, this exacerbation of symptoms is not temporally related to changes in serum LH, FSH and androgen concentrations. The differences in the timing of these biochemical and clinical phenomena raises the possibility of a direct effect of GnRH analogues at the level of the tumour. This present study explored the direct effects of GnRH analogues on prostatic cancer cells in culture and in vivo. GnRH analogue binding to human prostatic cancer cells grown in culture and biopsy samples was first examined. GnRH binding sites were characterised in cell lines and in human tumours. The biological effects of GnRH on prostatic cancer cells and a possible autocrine stimulatory role of GnRH-like peptides were investigated.
Materials and methods

Cell culture
The human androgen-sensitive prostatic cancer cell line LNCaP (isolated from lymph node metastasis; Horoszewicz et al., 1983) (Bradford, Biological response studies Exponentially growing cells were harvested using 0.1 % EDTA, counted with 0.2% trypan blue and washed once with PBS. One million cells per flask were seeded in T-25 flasks in 5 ml of RPMI 1640 medium containing 10% charcoal stripped fetal calf serum. Fresh medium containing various concentrations of buserelin with or without a 100-fold excess of the GnRH antagonist D-pGlul, D-Phe2, DTrp3'6) GnRH (Sigma, UK) was added every third day. After 10 days the cells were harvested with 0.1% EDTA, washed once with PBS and counted with 0.2% trypan blue. Total DNA was estimated by Burton's method (Burton, 1956 ).
GnRH radioimmunoassay
The cells were cultured in RPMI 1640 medium containing 10% charcoal stripped fetal calf serum. The medium was collected after 2 weeks, without refeeding, acidified with 0. 1% trifluoroacetic acid and centrifuged at 5,000 g for 10 min. The pellet was discarded and the supernatant was passed through C-18 Sep-Pak cartridge (Millipore, UK) (prewetted with methanol) followed by acidified water. The retained portion was eluted with 60% acetonitrile in water. There was 70% recovery of a control solution of buserelin added to fresh culture medium after a similar extraction procedure. The cytosol preparations from human prostatic samples were similarly concentrated. The eluates were examined for GnRH-like activity using GnRH radioimmunoassay kit (Amersham, UK). The sensitivity of the assay was 0.25 fmol per tube, inter-assay variation 7% and intra-assay effects on cell growth were seen in short term culture. The stimulatory and inhibitory effects of buserelin on androgensensitive LNCaP cells were partially blocked when 100-fold excess of GnRH-antagonist was added to the culture medium ( Figure 6 ).
Prostatic cancer cells secrete GnRH-like material
The observation that GnRH binding resulted in growth stimulation raised the possibility of the secretion of GnRHlike peptides by LNCaP cells themselves. We therefore examined this using a specific radioimmunoassay. The GnRH radioimmunoassay detected GnRH-like immunoreactivity in concentrated medium collected after two weeks culture of both cell lines. The concentrated culture media from 2 and 20 million LNCaP cells showed the presence of 3 and 30 fmol of GnRH-like immunoreactivity respectively (Figure 1 (Table I ). The elution profile on high performance liquid chromatography of this peptide was identical to native GnRH.
Discussion
Extrapituitary receptors for GnRH have been described in normal testis and ovary (Clayton et al., 1979 (Clayton et al., , 1980 . There have also been reports of the presence of GnRH-binding sites in breast cancer cells (Eidne et al., 1987) , pancreatic tumours (Szende et al., 1989) and induced rat prostatic cancers (Kadar et al., 1988) . The binding of GnRH to breast cancer cells has been shown to result in growth modulation (Millar et al., 1985; Eidne et al., 1987) . The finding of specific GnRH-binding sites in prostatic cancer cells which modulate growth, and the observation of the secretion of GnRH-like peptides by these cells, suggests that GnRH-like peptides may play an autocrine stimulatory role in this system. It is not yet known whether GnRH itself has mitogenic activity nor whether it has synergy with other stimulatory growth factors, and this requires further investigations. The results of our study provide impetus for the development of GnRH antagonists for use in prostatic cancer treatment.
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